Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 4/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.43 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3873204 | 0.82 | AGTR1 (0.48) | AGTR1AGTR2PDE4APDE4BPDE4C | |
| SCHEMBL14573929 | 0.82 | AGTR1 (0.41) | AGTR1S1PR2S1PR1S1PR3LPAR2 | |
| SCHEMBL489527 | 0.80 | AGTR1 (0.49) | AGTR1HRH4HRH3S1PR2S1PR1 | |
| SCHEMBL3950208 | 0.80 | AGTR1 (0.49) | AGTR1HRH4HRH3S1PR2S1PR1 | |
| SCHEMBL4638349 | 0.79 | AGTR1 (0.47) | AGTR1SMN1; SMN2ABCG2 | |
| SCHEMBL3883657 | 0.78 | AGTR1 (0.47) | AGTR1HRH3SMN1; SMN2ABCG2 | |
| SCHEMBL12746490 | 0.78 | AGTR1 (0.47) | AGTR1SMN1; SMN2AGTR2ABCG2 | |
| SCHEMBL3875056 | 0.78 | AGTR1 (0.49) | AGTR1SMN1; SMN2AGTR2ABCG2 | |
| SCHEMBL9541811 | 0.77 | AGTR1 (0.50) | AGTR1HRH4HRH3S1PR2S1PR1 | |
| SCHEMBL489121 | 0.77 | AGTR1 (0.50) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236839-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20120088919-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-8106082-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20110021585-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-7834041-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-20090093417-A1 | Dual-acting antihypertensive agents | THERAVANCE, INC. | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093417-A1 | Dual-acting antihypertensive agents | AGTR1, REN, AGTR2 | AGTR1 1/4885HRH4 201/4885HRH3 270/4885 |
| US-20110021585-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | AGTR1 1/4885HRH4 201/4885HRH3 270/4885 |
| US-20120088919-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | AGTR1 1/4885HRH4 201/4885HRH3 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.